Ruchi obtained her Bachelor’s and Master’s degree in Biochemistry from Delhi University, India. In 2012, she obtained her PhD from the University of Groningen, the Netherlands focused on designing of novel strategies to target nanobiologicals to key pathogenic cells in the chronic diseases (liver fibrosis and cancer). During the last stages of her PhD, she received two prestigious grants Sheila Sherlock research fellowship (from European association for the study of liver diseases, EASL) and The Ruth and Richard Julin’s Foundation Swedish research grant to pursue her postdoctoral research at the Karolinska Institute, Stockholm, Sweden. Her research project was focused on “Understanding the fundamental disease mechanisms behind Hepatitis C virus (HCV)-induced and alcohol-induced liver diseases”. In October 2012, she moved to the Netherlands and started as a senior postdoctoral researcher at the Department of Biomaterials Science and Technology at the University of Twente. Her aim was to combine fundamental disease understanding to identify new disease targets to develop (nano)biotherapeutics against liver diseases. In 2014, she received the prestigious VENI grant (from ZonMw, NWO) to pursue her research on “Development of novel targeted nano-therapeutics for the treatment of liver diseases”. From 2016-2019, she was an appointed as an Assistant Professor at the Department of Biomaterials Science and Technology. In 2019, she moved to the Department of Medical Cell BioPhysics, University of Twente where established her research group "Translational Liver Research". She has received several awards, published >60 publications, and obtained several research grants for pursuing her research. She has also served as a young academy board member, faculty council member and Twente graduate school award jury member. She participate in editorial board of several journals, evaluation committees and advisory boards.
My research group, Translational Liver Research, focuses on multiple research lines: 1) understanding the underlying disease mechanisms and cellular crosstalk, 2) identification of new therapeutic and diagnostic targets, 3) non-invasive detection methods and single-cell analysis, 4) designing of novel cell‐specific (nano)therapeutics (and theranostics), and 5) development of new in vitro culture systems and in vivo (preclinical animal models). The group broadly focuses on fibrotic and inflammatory liver diseases, and (liver) cancer.
UT Research Information System
Google Scholar Link
I have successfully completed my University teaching qualification (UTQ)/Basis Kwalificatie Onderwijs (BKO) in 2017, and English proficiency assessment (C1/C2) in 2019.
Since 2015, I am an organizer, coordinator and teacher of Controlled Drug and Gene delivery Master course (5EC). Due to the excellent performance of Controlled Drug and Gene delivery master course (graded 8.3 by students). This course was included in BME NVAO accreditation in 2018 and received positive remarks. I am coordinating M1 bachelor module, and Biochemistry master course.
I also supervise capita selecta, bachelor and master students during their internships and thesis assignments. I have also served as an advisor for ATLAS students and as a master Honor’s program supervisor.
Affiliated Study Programmes
Courses Academic Year 2023/2024
Courses Academic Year 2022/2023
- ATX-Liver.Evaluation of Novel Autotaxin Inhibitors for the Treatment of Liver Diseases, funded by TKI-HTSM grant.
- Chemokine receptor CCR2 and CCR8 peptide antagonists as a promising treatment for nonalcoholic steatohepatitis (NASH), funded by EASL.
- Healing wounds with Phototherapy, funded by the Pioneers in Healthcare (PIHC) project grant.
- Metabolic reprogramming of fatty liver diseases, funded by the Twente University RadBoudumc Opportunities (TURBO) grant.
- Bioactive liposomes for the treatment of non-alcoholic steatohepatitis (NASH), funded by the Phospholipid research council grant.
- Novel and Versatile Theranostics for diagnosis and therapy of liver fibrosis, funded by BOOSTER project (UT-WWU), Cross-border Collaboration UT Twente-WWU Muenster On Imaging for Diagnosis and Therapy.
- MDR-Phage - Small molecules that promote bacterial killing in phagocytes, funded by the NWO-TTW NACTAR grant.
- NanoNASH program, Joint Co-PI with Prof. Gert Storm, funded by NUS:
- Lipoxygenases: From dissecting mechanism to targeted therapeutics for the treatment of non-alcoholic steatohepatitis (NASH), funded by the DAAD-PRIME.
- Vijf vrouwelijke UT-toppers in Viva-lijst van rolmodellen: ‘Ik vind het een eer’ | Foto | destentor.nl
- Vijf vrouwelijke UT-toppers in Viva-lijst van rolmodellen - 1Twente
- Vijf vrouwelijke UT-toppers in Viva-lijst van rolmodellen: ‘Ik vind het een eer’ | Enschede | tubantia.nl
- Vijf UT-onderzoekers in VIVA400 - U-Today
- News in Tubantia Jan 2020, Deze Twentse pioniers in de gezondheidszorg staan op de rand van een doorbraak https://lnkd.in/ghAcqK9
- Rising star, U-Today Science & Technology Magazine # 8. https://issuu.com/utnieuws/docs/utodaysciencemag8
- Interview highlighted in Lever May 2019
- Hind Rattan award 2019: https://www.utwente.nl/en/news/!/2019/2/178694/dr.-ruchi-bansal-received-hind-rattan-award
- AASLD Young investigator award 2018: https://www.utwente.nl/en/news/!/2018/12/448182/dr.-ruchi-bansal-awarded-with-prestigious-young-investigator-award
- Love your liver 2018: https://www.utoday.nl/science/65283/love-your-liver
- UEG National scholar award 2017: https://www.utwente.nl/en/news/!/2017/11/281902/ruchi-bansal-wins-uegs-national-scholar-award
- Research highlighted in Lever 2015 (http://www.hepatologie.org/files/LEVER%203_15.pdf).
- VENI NWO Grant 2014: https://www.utwente.nl/en/news/!/2014/7/208942/veni-grant-for-ruchi-bansal-for-the-development-of-targeted-nanotherapeutics-against-liver-fibrosis; https://issuu.com/utwente/docs/universiteit_twente_jaarverslag_201/53; https://www.utoday.nl/news/60335/Drie_UTonderzoekers_scoren_een_Venibeurs